This study is for people aged 12 and older with moderate-to-severe atopic dermatitis (AD). Atopic dermatitis is a skin condition that makes skin red and itchy. The study looks at how well a medicine called amlitelimab works when given under the skin.

• **Study Length:** Up to 64 weeks. This includes 48 weeks of treatment and a 16-week safety follow-up.
• **Visits Needed:** Up to 14 visits to the study center.
• **Eligibility:** Must have been part of a previous study with amlitelimab and be at least 12 years old.

The study compares two amlitelimab doses. Participants are those who responded well in past studies. They'll either keep the same dose, switch doses, or stop treatment to see if their condition stays the same. The study is "double-blind," meaning neither the participants nor the researchers know who is receiving which dose. This helps ensure fair results. Some people may not be allowed if they have certain health problems or didn't follow rules in past studies. This is a chance to join research that might help improve treatments for AD. Before joining, it's important to discuss with your family and doctor to make sure it's right for you.